x min read


Written by
Richard Sandle
Published on
August 14, 2017
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook

The worldwide marijuana legalization trend continues to gain momentum. In the U.S., Massachusetts recently became the first state in the eastern U.S. to legalize the adult recreational use of marijuana on July 28, 2017. The new laws in California legalizing recreational marijuana are expected to go into effect in January of 2018. Mexico just legalized medical marijuana last June. In Canada, legal recreational marijuana laws are expected to take effect in mid-2018. As more countries and states become legal, and marijuana becomes more accepted by the general population, marijuana, and its derivative products such as edibles, CBD oils, and marijuana infused drinks will also become more accepted, eventually creating a robust international market for such products. MEDRELEAF CORP COM NPV (OTCMKTS:MEDFF) is positioning itself to capitalize on this opportunity.For those readers that are not acquainted with MedReleaf Corp, it is a Health Canada Licensed Producer, and the first and only ISO 9001 certified medical cannabis producer in North America. Its mission is to improve the quality of life for patients and to expand the world’s understanding of cannabis through wide-ranging research initiatives. MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world. The Company is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis. On June 7, 2017, MedReleaf closed its initial public offering and secondary offering for aggregate gross proceeds of $100.7 million and the Company's common shares commenced trading on the Toronto Stock Exchange under the symbol "LEAF".On Aug. 8, 2017 MedReleaf Corp announced a milestone achievement with the completion of its first international export. The transaction is also noteworthy as the first ever import of medical cannabis oil to Brazil and serves as a demonstration of both the Company's commitment to international growth and to establishing its position as the leading source of cannabis-based pharmaceutical products globally. Neil Closner, CEO of MedReleaf Commented:

"This is an important step in achieving MedReleaf's goals of ensuring that patients in need around the world receive the highest quality cannabis-based pharmaceutical products available and in realizing our long-term growth plans."

MedReleaf Corp announced on July 17, 2017 a multi-year licensing and distribution agreement with Massachusetts-based CannaKorp Inc., makers of the world's first single-use, pod-based cannabis vaporizing system, the CannaCloud™. The CannaCloud is a pod-based cannabis vaporizing system that uses precisely measured, sealed and tested CannaCloud Pods containing dried, ground cannabis flower that will be produced and packaged by MedReleaf in Canada. The CannaCloud gives cannabis users the predictability and assurance to know what they are inhaling every time, without the hassle of grinding, measuring, and packing traditional vaporization consumption devices.On the financial front, fiscal year 2017 (ending March 31, 2017) financial reports indicate that MedReleaf successfully increased production capacity, reduced cash production costs, launched new cannabis oil products at its production facility in Markham, Ontario, and achieved sales of $40.3 million, an increase of 109% from the prior year. In July 2016, the Company also completed the purchase of a 210,596 square foot production facility in Bradford, Ontario ("Bradford Facility"), and phase 1 of the expansion complete and in production.The quarterly financial reports for the period ending March 31, 2017 highlighted the following:

  • Sales of $10.4 million, an increase of 51% year-over-year
  • Adjusted Product Contribution Margin of $7.4 million, an increase of 67% year-over-year
  • Adjusted EBITDA of $1.6 million, a decline of 17% year-over-year, as a result of increased investment in long-term growth initiatives and $0.6 million in one-time costs
  • Sold 1,167.3 kilograms of cannabis products, an increase of 97% year-over-year
  • Adjusted product contribution margin per gram sold of $6.34 compared to $7.49 in the prior year period
  • Cash cost per gram produced of $1.53 compared to $3.11 in the prior year period

Quarterly Month MEDFF ChartMEDFF stock has only been trading since June 9 when it opened $6.71. It traded to a high of $7.23 on June 13, 2017 and has since traded down to $6.09 where it is currently trading. Current market capitalization stands at $550.74 million, on 90.37 million shares outstanding as of August 11, 2017.MedReleaf Corp is well capitalized, has revenue growth, and is expanding in the rapidly growing cannabis industry. The savvy investor should keep a close eye on this stock. The next quarter or two should reveal big things. MEDFF looks to be a top pick for cannabis investors. We will be updating our subscribers as soon as we know more. For the latest updates on MEDFF, sign up below!Image courtesy of Josh Jensen via FlickrDisclosure: We have no position in MEDFF and have not been compensated for this article.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.

Recommended for You